麦迪卫康附属有意收购香港寰宇医诚智慧科技发展100%股权

Group 1 - The company, Mediwalcan (02159), announced that on January 20, 2026, its subsidiary signed a non-binding memorandum of understanding with a potential seller regarding the possible acquisition of 100% equity in Hong Kong Huanyu Yicheng Intelligent Technology Development Limited and its subsidiaries, collectively referred to as the "Target Group" [1] - The Target Group primarily provides artificial intelligence technology to global pharmaceutical and medical device companies, innovating pharmaceutical research and physician training through its specialized AI medical models [1] - The Target Group also utilizes its core Web3 blockchain technology to ensure the authenticity, security, and traceability of data [1]